155 related articles for article (PubMed ID: 31372638)
21. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.
Dubrot J; Lane-Reticker SK; Kessler EA; Ayer A; Mishra G; Wolfe CH; Zimmer MD; Du PP; Mahapatra A; Ockerman KM; Davis TGR; Kohnle IC; Pope HW; Allen PM; Olander KE; Iracheta-Vellve A; Doench JG; Haining WN; Yates KB; Manguso RT
Immunity; 2021 Mar; 54(3):571-585.e6. PubMed ID: 33497609
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
Li J; Yuan S; Norgard RJ; Yan F; Sun YH; Kim IK; Merrell AJ; Sela Y; Jiang Y; Bhanu NV; Garcia BA; Vonderheide RH; Blanco A; Stanger BZ
Cancer Discov; 2021 Mar; 11(3):736-753. PubMed ID: 33158848
[TBL] [Abstract][Full Text] [Related]
23. Functional Genomics In Vivo Reveal Metabolic Dependencies of Pancreatic Cancer Cells.
Zhu XG; Chudnovskiy A; Baudrier L; Prizer B; Liu Y; Ostendorf BN; Yamaguchi N; Arab A; Tavora B; Timson R; Heissel S; de Stanchina E; Molina H; Victora GD; Goodarzi H; Birsoy K
Cell Metab; 2021 Jan; 33(1):211-221.e6. PubMed ID: 33152324
[TBL] [Abstract][Full Text] [Related]
24. Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer.
Biancur DE; Kapner KS; Yamamoto K; Banh RS; Neggers JE; Sohn ASW; Wu W; Manguso RT; Brown A; Root DE; Aguirre AJ; Kimmelman AC
Cell Metab; 2021 Jan; 33(1):199-210.e8. PubMed ID: 33152323
[TBL] [Abstract][Full Text] [Related]
25. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Wei X; Yang J; Adair SJ; Ozturk H; Kuscu C; Lee KY; Kane WJ; O'Hara PE; Liu D; Demirlenk YM; Habieb AH; Yilmaz E; Dutta A; Bauer TW; Adli M
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28068-28079. PubMed ID: 33097661
[TBL] [Abstract][Full Text] [Related]
26. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Shu S; Wu HJ; Ge JY; Zeid R; Harris IS; Jovanović B; Murphy K; Wang B; Qiu X; Endress JE; Reyes J; Lim K; Font-Tello A; Syamala S; Xiao T; Reddy Chilamakuri CS; Papachristou EK; D'Santos C; Anand J; Hinohara K; Li W; McDonald TO; Luoma A; Modiste RJ; Nguyen QD; Michel B; Cejas P; Kadoch C; Jaffe JD; Wucherpfennig KW; Qi J; Liu XS; Long H; Brown M; Carroll JS; Brugge JS; Bradner J; Michor F; Polyak K
Mol Cell; 2020 Jun; 78(6):1096-1113.e8. PubMed ID: 32416067
[TBL] [Abstract][Full Text] [Related]
27.
León TE; Rapoz-D'Silva T; Bertoli C; Rahman S; Magnussen M; Philip B; Farah N; Richardson SE; Ahrabi S; Guerra-Assunção JA; Gupta R; Nacheva EP; Henderson S; Herrero J; Linch DC; de Bruin RAM; Mansour MR
Cancer Discov; 2020 Jul; 10(7):998-1017. PubMed ID: 32349972
[TBL] [Abstract][Full Text] [Related]
28. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
29. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells.
Williams JB; Li S; Higgs EF; Cabanov A; Wang X; Huang H; Gajewski TF
Nat Commun; 2020 Jan; 11(1):602. PubMed ID: 32001684
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.
Crowther MD; Dolton G; Legut M; Caillaud ME; Lloyd A; Attaf M; Galloway SAE; Rius C; Farrell CP; Szomolay B; Ager A; Parker AL; Fuller A; Donia M; McCluskey J; Rossjohn J; Svane IM; Phillips JD; Sewell AK
Nat Immunol; 2020 Feb; 21(2):178-185. PubMed ID: 31959982
[TBL] [Abstract][Full Text] [Related]
31. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.
Wei J; Long L; Zheng W; Dhungana Y; Lim SA; Guy C; Wang Y; Wang YD; Qian C; Xu B; Kc A; Saravia J; Huang H; Yu J; Doench JG; Geiger TL; Chi H
Nature; 2019 Dec; 576(7787):471-476. PubMed ID: 31827283
[TBL] [Abstract][Full Text] [Related]
32. Deciphering essential cistromes using genome-wide CRISPR screens.
Fei T; Li W; Peng J; Xiao T; Chen CH; Wu A; Huang J; Zang C; Liu XS; Brown M
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25186-25195. PubMed ID: 31727847
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
Wei L; Lee D; Law CT; Zhang MS; Shen J; Chin DW; Zhang A; Tsang FH; Wong CL; Ng IO; Wong CC; Wong CM
Nat Commun; 2019 Oct; 10(1):4681. PubMed ID: 31615983
[TBL] [Abstract][Full Text] [Related]
34. Spliceosomal disruption of the non-canonical BAF complex in cancer.
Inoue D; Chew GL; Liu B; Michel BC; Pangallo J; D'Avino AR; Hitchman T; North K; Lee SC; Bitner L; Block A; Moore AR; Yoshimi A; Escobar-Hoyos L; Cho H; Penson A; Lu SX; Taylor J; Chen Y; Kadoch C; Abdel-Wahab O; Bradley RK
Nature; 2019 Oct; 574(7778):432-436. PubMed ID: 31597964
[TBL] [Abstract][Full Text] [Related]
35. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
[TBL] [Abstract][Full Text] [Related]
36. A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.
Nagler A; Vredevoogd DW; Alon M; Cheng PF; Trabish S; Kalaora S; Arafeh R; Goldin V; Levesque MP; Peeper DS; Samuels Y
Pigment Cell Melanoma Res; 2020 Mar; 33(2):334-344. PubMed ID: 31549767
[TBL] [Abstract][Full Text] [Related]
37. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.
Tsui CK; Barfield RM; Fischer CR; Morgens DW; Li A; Smith BAH; Gray MA; Bertozzi CR; Rabuka D; Bassik MC
Nat Chem Biol; 2019 Oct; 15(10):949-958. PubMed ID: 31451760
[TBL] [Abstract][Full Text] [Related]
38. Chromatin architectural factor CTCF is essential for progesterone-dependent uterine maturation.
Hewitt SC; Gruzdev A; Willson CJ; Wu SP; Lydon JP; Galjart N; DeMayo FJ
FASEB J; 2023 Aug; 37(8):e23103. PubMed ID: 37489832
[TBL] [Abstract][Full Text] [Related]
39. Chromatin Organization and Transcriptional Programming of Breast Cancer Cell Identity.
Bobbitt JR; Seachrist DD; Keri RA
Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37394919
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells.
Hany D; Vafeiadou V; Picard D
Sci Adv; 2023 May; 9(19):eadd3685. PubMed ID: 37172090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
